Endo upfront and milestone payments guidance of $8 Endo planning on $89 million for upfront and milestone payments for next twelve months .76 cents per share going to that. I kinda hope 10 % of that will be ours. Lets hope. I will try to sneak a call in this morning for an update on Urocidin and try to plug our companies name in there. I will ask why the hush hush on stellar result from first phase 3 trial. Best i can do. hopefully some mention from analysts about progress.
JASL